# TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

> **NCT04589260** · PHASE1 · TERMINATED · sponsor: **Theravance Biopharma** · enrollment: 72 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** TD-1058
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04589260
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-15
- **Primary completion:** 2021-05-06
- **Final completion:** 2021-10-04
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** The Sponsor has decided to stop the study due to business reasons. Study was terminated before initiation of part C and D (Decision to not proceed with Parts C and D was not for safety reasons and do not impact the overall risk benefit of the IMP.)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04589260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04589260, "TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04589260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*